Merck Group and the Broad Institute inked a CRISPR-based genomic editing licensing agreement.
According to European Biotechnology, the contract simplifies and accelerates IP access to CRISPR for research purposes. It is hoped that this will contribute to shortening the drug development timelines.
The IP Agreement
Under the agreement with the Broad Institute, the Merck Group (Germany-based group) will have access to non-exclusive IP, jointly owned by the Broad Institute and its affiliates (including Harvard University, the Massachusetts of Technology, the New York Genome Center, New York University, Rockefeller University, the University of Iowa Research Foundation, Tokyo University, the Whitehead Institute for Biomedical Research, etc.). Merck does have some restrictions regarding the creation of rodent models.
With the Merck Bioethics Advisory Panel (MBAP), Merck has set up an independent, external bioethical advisory body to provide guidance for research involving its divisions. This includes research on or via genome editing. The company has also defined a clear operational position, taking into account scientific and societal issues, in order to pave the way for promising therapeutic approaches for use in research and applications